Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ABOGEN INC
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.
In immuno-oncology and beyond, Chinese investors are setting their sights on new targets in the biopharma arena.
Despite a pending domestic approval for BioNTech/Fosun's COVID-19 vaccine, China’s apparent belief in another, domestically developed, mRNA vaccine sees a large group of investors pour hundreds of millions into a little-known private bioventure founded by an ex-Moderna scientist and poised to take on the US biotech.